Ask AI
MF Treatment Tool
Expert Guidance for the Selection of Systemic Agents in Myelofibrosis

Released: October 30, 2026

Introduction

The expanding range of JAK inhibitor options in myelofibrosis has increased the need for individualized treatment decisions that account for disease characteristics, molecular findings, prior therapy, comorbidities, cytopenias, symptoms, and patient-specific goals. This Interactive Decision Support Tool applies key patient and disease characteristics to treatment selections and compares their intended approach with recommendations from MF experts, exploring how clinical evidence, supportive care needs, and patient factors can inform personalized, equitable management across diverse patient populations.

Interactive Decision Support Tool

Expert Guidance for the Selection of Systemic Agents in Myelofibrosis

Disclaimer

Access to and use of the Interactive Decision Support Tool titled “Expert Guidance for Systemic Therapy in Myelofibrosis” are subject to the following terms and conditions.

Please read these terms carefully.

This tool educates healthcare professionals about management options for patients with MF. The recommendations reflect the individual expert guidance of John Mascarenhas, MD; Abdulraheem Yacoub, MD; Brady L. Stein, MD, MHS; Kristen Pettit, MD; and Raajit Rampal, MD, PhD. They do not establish a single preferred regimen or a panel consensus.


Materials published by Decera Clinical Education reflect the views of the authors or reviewers, rather than necessarily those of the educational provider or grant supporters. The activity may discuss uses or doses that are not approved by the FDA. Healthcare professionals should review the full current prescribing information, available evidence, and patient-specific factors before treatment.


Although this tool has been developed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of the information, individually or in aggregate. Decera Clinical Education provides this information on an as-is basis. All warranties, including merchantability, fitness for a particular purpose, freedom from computer viruses, and noninfringement of proprietary rights, are disclaimed.


Any trademarks are the property of their respective companies.

© 2026 Decera Clinical Education. All rights reserved.

Program Content